Common Multiple Sclerosis Drug Could Reverse Physical Symptoms
Many treatments exist to help people with relapsing-remitting multiple sclerosis (RRMS) reduce the number and frequency of remissions, and one such existing treatment could offer an even greater benefit.
The MS drug alemtuzumab is a drug currently used to treat patients with RRMS and reduce the number of relapses they experience as well as the severity of the symptoms.
Note: Alemtuzumab has the highest, most severe risk of side effects among similar medications. Doctors usually reserve this drug for patients who have not responded to other medications.
Researchers at the Queen Mary University of London conducted a two-year study of the benefits of alemtuzumab treatment when administered earlier.
The researchers treated one group of 426 people with RRMS with alemtuzumab while they treated the other group of 202 people with RRMS with interferon beta-1a. The researchers assessed each person’s level of disability from before treatment and then in three-month intervals for two years.
At the conclusion of the two-year treatment period, approximately 28 percent of the patients treated with alemtuzumab showed improvement in their disability test by one or more points (on a scale of 0-10), while the other group only showed about 15 percent of participants improve a point or better.
The researchers, who detailed their findings in Neurology, say longer studies will be necessary to compile a full risk-benefit analysis of alemtuzumab treatment.
Multiple Sclerosis Can Prevent You from Working — We Can Help
The Disability Help Group provides assistance and guidance to disabled people seeking Social Security disability benefits. If you can no longer work and earn a substantial income, call us at 800-800-2009 to speak with our disability advocates about your right to disability benefits.